Researchers overturn the prevailing theory for colorectal tumor initiation

FHS
May 29, 2024
7:24 pm

Research led by Weill Cornell Medicine provides new evidence that most colorectal cancers begin with the loss of intestinal stem cells, even before cancer-causing genetic alterations appear.

FDA again rejects AbbVie’s continuous infusion therapy for Parkinson’s

The FDA has rejected a new Parkinson’s drug from AbbVie for a second time. Regulators turned away ABBV-951, a 24-hour infusion therapy to treat advanced

June 26, 2024

Medtronic isn’t afraid of Wegovy’s potential to disrupt

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here

November 22, 2023

BlossomHill raises $100M in bid to repeat founders’ cancer success at Turning Point

BlossomHill Therapeutics has closed a $100 million Series B to bring three of its oncology small molecules into the clinic and collect early efficacy data

March 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.